术前放疗联合手术对比单纯手术治疗原发性腹膜后肉瘤:STRASS Ⅲ期随机试验
术前放疗组3-4级不良事件(尤其淋巴细胞减少)和严重不良事件更常见。研究认为术前放疗不应作为腹膜后肉瘤的标准治疗。
要点
- 术前放疗联合手术未改善腹膜后肉瘤患者的腹部无复发生存期。
- 术前放疗组3-4级淋巴细胞减少发生率达77%,显著高于单纯手术组的1%。
- 术前放疗不应作为原发性腹膜后肉瘤的标准治疗。
核心结论
- 术前放疗不应被视为腹膜后肉瘤的标准治疗。
研究设计与样本
- EORTC-62092(STRASS)为多中心、开放标签、随机Ⅲ期试验,在13个国家的31家机构开展。
- 纳入266例年龄≥18岁、组织学证实的局限性原发性可手术腹膜后肉瘤患者,按1:1随机分至术前放疗联合手术组(133例)或单纯手术组(133例)。
主要发现
- 术前放疗联合手术组最常见的3-4级不良事件为淋巴细胞减少(98/127,77%)、贫血(15/127,12%)和低白蛋白血症(15/127,12%);单纯手术组分别为1/128(1%)、10/128(8%)和5/128(4%)。
- 术前放疗联合手术组严重不良事件发生率为30/127(24%),单纯手术组为13/128(10%)。
- 术前放疗联合手术组有1/127(1%)患者因治疗相关严重不良事件(胃胸膜瘘)死亡,单纯手术组无治疗相关死亡。
临床怎么用
- 对于原发性局限性腹膜后肉瘤,不应将术前放疗作为标准治疗推荐。
- 术前放疗可增加3-4级淋巴细胞减少等不良事件及严重不良事件风险,临床决策需权衡毒性。
局限性
- 原文未报告本研究的局限性相关内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Unlike for extremity sarcomas, the efficacy of radiotherapy for retroperitoneal sarcoma is not established. The aim of this study was to evaluate the impact of preoperative radiotherapy plus surgery versus surgery alone on abdominal recurrence-free survival. METHODS: EORTC-62092 is an open-label, randomised, phase 3 study done in 31 research institutions, hospitals, and cancer centres in 13 countries in Europe and North America. Adults (aged ≥18 years) with histologically documented, localised, primary retroperitoneal sarcoma that was operable and suitable for radiotherapy, who had not been previously treated and had a WHO performance status and American Society of Anesthesiologists score of 2 or lower, were centrally randomly assigned (1:1), using an interactive web response system and a minimisation algorithm, to receive either surgery alone or preoperative radiotherapy followed by surgery. Randomisation was stratified by hospital and performance status. Radiotherapy was delivered as 50·4 Gy (in 28 daily fractions of 1·8 Gy) in either 3D conformal radiotherapy or intensity modulated radiotherapy, and the objective of surgery was a macroscopically complete resection of the tumour mass with en-bloc organ resection as necessary. The primary endpoint was abdominal recurrence-free survival, as assessed by the investigator, and was analysed in the intention-to-treat population. Safety was analysed in all patients who started their allocated treatment. This trial is registered with ClinicalTrials.gov, NCT01344018. FINDINGS: Between Jan 18, 2012 and April 10, 2017, 266 patients were enrolled, of whom 133 were randomly assigned to each group. The median follow-up was 43·1 months (IQR 28·8-59·2). 128 (96%) patients from the surgery alone group had surgery, and 119 (89%) patients in the radiotherapy and surgery group had both radiotherapy and surgery. Median abdominal recurrence-free survival was 4·5 years (95% CI 3·9 to not estimable) in the radiotherapy plus surgery group and 5·0 years (3·4 to not estimable) in the surgery only group (hazard ratio 1·01, 95% CI 0·71-1·44; log rank p=0·95). The most common grade 3-4 adverse events were lymphopenia (98 [77%] of 127 patients in the radiotherapy plus surgery group vs one [1%] of 128 patients in the surgery alone group), anaemia (15 [12%] vs ten [8%]), and hypoalbuminaemia (15 [12%] vs five [4%]). Serious adverse events were reported in 30 (24%) of 127 patients in the radiotherapy plus surgery group, and in 13 (10%) of 128 patients in the surgery alone group. One (1%) of 127 patients in the radiotherapy plus surgery group died due to treatment-related serious adverse events (gastropleural fistula), and no patients in the surgery alone group died due to treatment-related serious adverse events. INTERPRETATION: Preoperative radiotherapy should not be considered as standard of care treatment for retroperitoneal sarcoma. FUNDING: European Organisation for Research and Treatment of Cancer, and European Clinical Trials in Rare Sarcomas.
引用
- Bonvalot S, Gronchi A, Le Péchoux C, et al. Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2020. PMID: 32941794. doi:10.1016/S1470-2045(20)30446-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。